Data came from a first-in-human study of 23 patients with glaucoma or ocular hypertension. They received the IOL implant at the time of cataract surgery. The company reported a consistent sustained reduction of intraocular pressure (IOP) across all three dose strengths. Subjects achieved a mean pressure reduction of 43.7% at month 18 compared with baseline.
Additionally, SpyGlass reports that 100% of patients remained off all topical IOP-lowering drops. All patients achieved an IOP reduction of more than 20% from baseline and 96% of patients maintained an IOP ≤18 mmHg through month 18. Investigators reported that patients tolerated the SpyGlass platform well, with zero product-related adverse events.
The SpyGlass platform utilizes standard surgical techniques, meaning cataract surgeons don’t need to learn new skills to adopt. It delivers three years of bimatoprost to targeted tissues. The company plans to share longer-term data in the coming months and complete enrollment in a Phase I/II U.S. study this year. It hopes to pursue FDA approval for the IOL drug delivery platform.
“The clinical results achieved by the SpyGlass drug delivery platform, now 18 months post-implantation, continue to be compelling for ophthalmic surgeons and for patients living with glaucoma,” said Dr. Malik Kahook, co-founder of SpyGlass Pharma. “Long-term drug delivery of trusted medicine is a major unmet need for patients living with chronic eye conditions. The results presented showcase the potential of the SpyGlass drug delivery platform to be a game changer for glaucoma patients and all cataract surgeons.”
